Here we report a metabolomics discovery study conducted on blood serum samples of patients in different stages of chronic kidney disease (CKD). Metabolites were monitored on a quality controlled holistic platform combining reversed-phase liquid chromatography coupled to high-resolution quadrupole time-of-flight mass spectrometry in both negative and positive ionization mode and gas chromatography coupled to quadrupole mass spectrometry. A substantial portion of the serum metabolome was thereby covered. Eighty-five metabolites were shown to evolve with CKD progression of which 43 metabolites were a confirmation of earlier reported uremic retention solutes and/or uremic toxins. Thirty-one unique metabolites were revealed which were increasing significantly throughout CKD progression, by a factor surpassing the level observed for creatinine, the currently used biomarker for kidney function. Additionally, 11 unique metabolites showed a decreasing trend.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Ahmad, S., Dasgupta, A., & Kenny, M. A. (1989). Fatty acid abnormalities in haemodialysis patients: Effect of l-carnitine administration. Kidney International Supplement, 27, S243–S246.
Aronov, P. A., Luo, F. J., Plummer, N. S., et al. (2011). Colonic contribution to uremic solutes. Journal of the American Society of Nephrology, 22, 1769–1776.
Begley, P., Francis-McIntyre, S., Dunn, W. B., et al. (2009). Development and performance of a gas chromatography–time-of-flight mass spectrometry analysis for large-scale nontargeted metabolomic studies of human serum. Analytical Chemistry, 81, 7038–7046.
Bellinghieri, G., Santoro, D., Calvani, M., Mallamace, A., & Savica, V. (2003). Carnitine and haemodialysis. American Journal of Kidney Diseases, 41(3), S116–S122.
Benjamini, Y., & Hochberg, Y. (1995). Controlling the false discovery rate: A practical and powerful approach to multiple testing. Journal of the Royal Statistical Society: Series B, 57(1), 289–300.
Benton, H. P., Wong, D. M., Trauger, S. A., & Siuzdak, G. (2008). XCMS2: processing tandem mass spectrometry data for metabolite identification and structural characterization. Analytical Chemistry, 80(16), 6382–6389.
Bultitude, F. W., & Newham, S. J. (1975). Identification of some abnormal metabolites in plasma from uremic subjects. Clinical Chemistry, 21, 1329–1334.
Busch, M., Gobert, A., Franke, S., et al. (2010). Vitamin B-6 metabolism in chronic kidney disease—Relation to transsulfuration, advanced glycation and cardiovascular disease. Nephron Clinical Practice, 114, C38–C46.
Chen, J., Zhao, X., Fritsche, J., et al. (2008). Practical approach for the identification and isomer elucidation of biomarkers detected in a metabonomic study for the discovery of individuals at risk for diabetes by integrating the chromatographic and mass spectrometric information. Analytical Chemistry, 80(4), 1280–1289.
Cohen, G., Raupachova, J., Wimmer, T., Deicher, R., & Hörl, W. H. (2008). The uraemic retention solute para-hydroxy-hippuric acid attenuates apoptosis of polymorphonuclear leukocytes from healthy subjects but not from haemodialysis patients. Nephrol. Dialysis Transplantation, 23(8), 2512–2519.
Dasgupta, A., Kenny, M. A., & Ahmad, S. (1990). Abnormal fatty-acid profile in chronic-haemodialysis patients—Possible deficiency of essential fatty-acids. Clinical Physiology & Biochemistry, 8, 238–243.
Dudley, E., Lemière, F., Van Dongen, W., et al. (2004). Analysis of urinary nucleosides. IV. Identification of urinary purine nucleosides by liquid chromatography/electrospray mass spectrometry. Rapid Communications in Mass Spectrometry, 18, 2730–2738.
Dudley, E., Tuytten, R., Bond, A., et al. (2005). Study of the mass spectrometric fragmentation of pseudouridine: comparison of fragmentation data obtained by matrix-assisted laser desorption/ionisation post-source decay, electrospray ion trap multistage mass spectrometry, and by a method utilising electrospray quadrupole time-of-flight tandem mass spectrometry and in-source fragmentation. Rapid Communications in Mass Spectrometry, 19, 3075–3085.
Duranton, F., Cohen, G., De Smet, R., et al. (2012). Normal and pathologic concentrations of uremic toxins. Journal of the American Society of Nephrology, 23, 1258–1270.
Fiehn, O., & Kind, T. (2007). Metabolite profiling in blood plasma. Methods in Molecular Biology, 358, 3–17.
Flugel-Link, R. M., Jones, M. R., & Kopple, J. D. (1983). Red cell and plasma amino acid concentrations in renal failure. Journal of Parenteral and Enteral Nutrition, 7, 450–456.
Hayashi, K., Sasamura, H., Hishiki, T., et al. (2011). Use of serum and urine metabolome analysis for the detection of metabolic changes in patients with stage 1–2 chronic kidney disease. Nephro-Urology Monthly, 3(3), 164–171.
Herget-Rosenthal, S., Glorieux, G., Jankowski, J., & Jankowski, V. (2009). Uremic toxins in acute kidney injury. Seminars in Dialysis, 22, 445–448.
Hill, A. W., & Mortishire-Smith, R. J. (2005). Automated assignment of high-resolution collisionally activated dissociation mass spectra using a systematic bond disconnection approach. Rapid Communications in Mass Spectrometry, 19, 3111–3118.
Jankowski, J., Tepel, M., Stephan, N., et al. (2001). Characterization of p-hydroxy-hippuric acid as an inhibitor of Ca2+ -ATPase in end-stage renal failure. Kidney International Supplement, 78, S84–S88.
Jia, L., Chen, J., Yin, P., Lu, X., & Xu, G. (2008a). Serum metabonomics study of chronic renal failure by ultra performance liquid chromatography coupled with Q-TOF mass spectrometry. Metabolomics, 4, 183–189.
Jia, L., Schweikart, K., Tomaszewski, J., et al. (2008b). Toxicology and pharmacokinetics of 1-methyl-d-tryptophan: absence of toxicity due to saturating absorption. Food and Chemical Toxicology, 46, 203–211.
Jia, L., Wang, C., Zhao, S., Lu, X., & Xu, G. (2007). Metabolomic identification of potential phospholipid biomarkers for chronic glomerulonephritis by using high performance liquid chromatography–mass spectrometry. Journal of Chromatography B, 860, 134–140.
Jiye, A., Trygg, J., Gullberg, J., et al. (2005). Extraction and GC/MS analysis of the human blood plasma metabolome. Analytical Chemistry, 77, 8086–8094.
Jourde-Chiche, N., Dou, L., Cerini, C., Dignat-George, F., Vanholder, R., & Brunet, P. (2009). Protein-bound toxins-update 2009. Seminars in Dialysis, 22, 334–339.
Ju, W., Smith, S., & Kretzler, M. (2012). Genomic biomarkers for chronic kidney disease. Translational Research, 159, 290–302.
Kikuchi, K., Itoh, Y., Tateoka, R., Ezawa, A., Murakami, K., & Niwa, T. (2010). Metabolomic analysis of uremic toxins by liquid chromatography/electrospray ionization-tandem mass spectrometry. Journal of Chromatography B, 878, 1662–1668.
Kind, T., Wohlgemuth, G., Lee, D. Y., et al. (2009). FiehnLib: mass spectral and retention index libraries for metabolomics based on quadrupole and time-of-flight gas chromatography/mass spectrometry. Analytical Chemistry, 81, 10038–10048.
Kumps, A., Duez, P., & Mardens, Y. (2002). Metabolic, nutritional, iatrogenic, and artifactual sources of urinary organic acids: a comprehensive table. Clinical Chemistry, 48, 708–717.
Kussmann, M., Raymond, F., & Affolter, M. (2006). OMICS-driven biomarker discovery in nutrition and health. Journal of Biotechnology, 124, 758–787.
Lawrence, J. R., Peter, R., Baxter, G. J., Robson, J., Graham, A. B., & Paterson, J. R. (2003). Urinary excretion of salicyluric and salicylic acids by non-vegetarians, vegetarians, and patients taking low dose aspirin. Journal of Clinical Pathology, 56(9), 651–653.
Lees, H., Swann, J. R., Wilson, I. D., Nicholson, J. K., & Holmes, E. (2013). Hippurate: the natural history of a mammalian-microbial co-metabolite. Journal of Proteome Research. doi:10.1021/pr300900b.
Levey, A. S., Coresh, J., Balk, E., et al. (2003). National kidney foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Annals of Internal Medicine, 139, 137–147.
Lipkin, G. W., Forbes, M. A., Cooper, E. H., & Turney, J. H. (1993). Hyaluronic acid metabolism and its clinical significance in patients treated by continuous ambulatory peritoneal dialysis. Nephrology Dialysis Transplantation, 8(4), 357–360.
Meert, N., Schepers, E., Glorieux, G., et al. (2012). Novel method for simultaneous determination of p-cresylsulphate and p-cresylglucuronide: Clinical data and pathophysiological implications. Nephrology Dialysis Transplantation, 27, 2388–2396.
Mischak, H., Allmaier, G., Apweiler, R., et al. (2010). Recommendations for biomarker identification and qualification in clinical proteomics. Science Translational Medicicne, 2(46), 46ps42.
Mischak, H., Massy, Z. A., & Jankowski, J. (2009). Proteomics in uremia and renal disease. Seminars in Dialysis, 22, 409–416.
Niwa, T., Takeda, N., & Yoshizumi, H. (1998). RNA metabolism in uremic patients: Accumulation of modified ribonucleosides in uremic serum—Technical note. Kidney International, 53, 1801–1806.
Palazoglu, M., & Fiehn, O. (2009). Metabolite identification in blood plasma using GC/MS and the Agilent Fiehn GC/MS metabolomics RTL library. Agilent Application Note 5990-3638EN. Palo Alto, CA: Agilent Technologies.
Perco, P., Pleban, C., Kainz, A., et al. (2006). Protein biomarkers associated with acute renal failure and chronic kidney disease. European Journal of Clinical Investigation, 36, 753–763.
Pero, R. W. (2010). Health consequences of catabolic synthesis of hippuric acid in humans. Current Clinical Pharmacology, 5(1), 67–73.
Pletinck, A., Vanholder, R., & Glorieux, G. (2012). p-Cresyl sulfate. In T. Niwa (Ed.), Uremic toxins. Hoboken: Wiley. doi:10.1002/9781118424032.ch5.
Qi, S., Ouyang, X., Wang, L., Peng, W., Wen, J., & Dai, Y. (2012). A pilot metabolic profiling study in serum of patients with chronic kidney disease based on (1) H-NMR-spectroscopy. Clinical and Translational Science, 5(5), 379–385.
Rechner, A. R., Spencer, J. P., Kuhnle, G., Hahn, U., & Rice-Evans, C. A. (2001). Novel biomarkers of the metabolism of caffeic acid derivatives in vivo. Free Radical Biology & Medicine, 30(11), 1213–1222.
Rhee, E. P., Souza, A., Farrell, L., et al. (2010). Metabolite profiling identifies markers of uremia. Journal of the American Society of Nephrology, 21, 1041–1051.
Salisbury, P. F., Dunn, M. S., & Murphy, E. A. (1957). Apparent free amino acids in deproteinized plasma of normal and uremic persons. Journal of clinical Investigation, 36, 1227–1232.
Sana, T. R., Roark, J. C., Li, X., Waddell, K., & Fischer, S. M. (2008). Molecular formula and METLIN personal metabolite database matching applied to the identification of compounds generated by LC/TOF–MS. Journal of Biomolecular Techniques, 19(4), 258–266.
Sato, E., Kohno, M., Yamamoto, M., Fujisawa, T., Fujiwara, K., & Tanaka, N. (2011). Metabolomic analysis of human plasma from haemodialysis patients. European Journal of Clinical Investigation, 41, 241–255.
Seppala, R., Renlund, M., Bernardini, I., Tietze, F., & Gahl, W. A. (1990). Renal handling of free sialic acid in normal humans and patients with Salla disease or renal disease. Laboratory Investigation, 63(2), 197–203.
Shah, V. O., Townsend, R. R., Feldman, H. I., Pappan, K. L., Kensicki, E., & Vander Jagt, D. L. (2013). Plasma metabolomic profiles in different stages of CKD. Clinical Journal of the American Society of Nephrology. doi:10.2215/CJN.05540512.
Smith, C. A., O’Maille, G., Want, E. J., et al. (2005). METLIN: A metabolite mass spectral database. Therapeutic Drug Monitoring, 27(6), 747–751.
Smith, C. A., Want, E. J., O’Maille, G., Abagyan, R., & Siuzdak, G. (2006). XCMS: Processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Analytical Chemistry, 78(3), 779–787.
Spagou, K., Wilson, I. D., Masson, P., et al. (2011). HILIC–UPLC–MS for exploratory urinary metabolic profiling in toxicological studies. Analytical Chemistry, 83, 382–390.
Spasovski, G., Ortiz, A., Vanholder, R., & El Nahas, M. (2011). Proteomics in chronic kidney disease: The issues clinical nephrologists need an answer for. Proteomics Clinical Applications, 5, 233–240.
Stanislaus, A., Guo, K., & Li, L. (2012). Development of an isotope labeling ultra-high performance liquid chromatography mass spectrometric method for quantification of acylglycines in human urine. Analytica Chimica Acta, 750, 161–172.
T’Kindt, R., Scheltema, R. A., Jankevics, A., et al. (2010). Metabolomics to unveil and understand phenotypic diversity between pathogen populations. PLoS Neglected Tropical Diseases, 4(11), e904.
Tao, X., Liu, Y., Wang, Y., et al. (2008). GC–MS with ethyl chloroformate derivatization for comprehensive analysis of metabolites in serum and its application to human uremia. Analytical and Bioanalytical Chemistry, 391, 2881–2889.
Tautenhahn, R., Cho, K., Uritboonthai, W., Zhu, Z., Patti, G. J., & Siuzdak, G. (2012). An accelerated workflow for untargeted metabolomics using the METLIN database. Nature Biotechnology, 30(9), 826–828.
Toyohara, T., Akiyama, Y., Suzuki, T., et al. (2010). Metabolomic profiling of uremic solutes in CKD patients. Hypertension Research, 33, 944–952.
Turney, J. H., Davison, A. M., Forbes, M. A., & Cooper, E. H. (1991). Hyaluronic acid in end-stage renal failure treated by haemodialysis: clinical correlates and implications. Nephrology Dialysis Transplantation, 6, 566–570.
Vanholder, R., Bammens, B., de Loor, H., et al. (2011). Warning: the unfortunate end of p-cresol as a uraemic toxin. Nephrology Dialysis Transplantation, 26, 1464–1467.
Vanholder, R., De Smet, R., Glorieux, G., et al. (2003a). Review on uremic toxins: Classification, concentration, and interindividual variability. Kidney International, 63, 1934–1943.
Vanholder, R., Glorieux, G., De Smet, R., & Lameire, N. (2003b). New insights in uremic toxins. Kidney International, 63, S6–S10.
Vaziri, N. D. (2012). CKD impairs barrier function and alters microbial flora of the intestine: a major link to inflammation and uremic toxicity. Current Opinion in Nephrology and Hypertension, 21(6), 587–592.
Vazquez, S., Truscott, R. J., O’Hair, R. A., Weimann, A., & Sheil, M. M. (2001). A study of kynurenine fragmentation using electrospray tandem mass spectrometry. Journal of the American Society for Mass Spectrometry, 12(7), 786–794.
Weimann, A., Sabroe, M., & Poulsen, H. E. (2005). Measurement of caffeine and five of the major metabolites in urine by high-performance liquid chromatography/tandem mass spectrometry. Journal of Mass Spectrometry, 40, 307–316.
Weiss, R. H., & Kim, K. (2012). Metabolomics in the study of kidney diseases. Nature Reviews Nephrology, 8, 22–33.
Wu, I., & Parikh, C. R. (2008). Screening for kidney diseases: Older measures versus novel biomarkers. Clinical Journal American Society of Nephrology, 3, 1895–1901.
Zhao, Y. Y., Cheng, X. L., Wei, F., et al. (2012a). Serum metabonomics study of adenine-induced chronic renal failure in rats by ultra performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry. Biomarkers, 17, 48–55.
Zhao, Y. Y., Liu, J., Cheng, X. L., Bai, X., & Lin, R. C. (2012b). Urinary metabonomics study on biochemical changes in an experimental model of chronic renal failure by adenine based on UPLC Q-TOF/MS. Clinica Chimica Acta, 413, 642–649.
Zhu, Z. J., Schultz, A. W., Wang, J., et al. (2013). Liquid chromatography quadrupole time-of-flight mass spectrometry characterization of metabolites guided by the METLIN database. Nature Protocols, 8(3), 451–460.
The authors acknowledge Steve Fischer (Agilent Technologies, Santa Clara, CA), Gordon Ross (Agilent Technologies, Cheadle, UK) and Kai Chen (Ghent University, Belgium) for their valuable input. This research was funded by the Flemish Agency for Innovation by Science and Technology (IWT, Flanders). JB was supported by an IWT study grant.
J. Boelaert and R. t’Kindt have contributed equally to this study.
Electronic supplementary material
Below is the link to the electronic supplementary material.
About this article
Cite this article
Boelaert, J., t’Kindt, R., Schepers, E. et al. State-of-the-art non-targeted metabolomics in the study of chronic kidney disease. Metabolomics 10, 425–442 (2014). https://doi.org/10.1007/s11306-013-0592-z
- Chronic kidney disease